GlassScriptPhysician profile
Ahmad Ramahi
NPI 1457872350
$35,322.48
in general payments reported to CMS, 2019-2025
20 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35K · 2022: $16.68 · 2023: $273 · 2024: $183 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.90 |
| Education | $144.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34,583.00 | 2020 | |
| Amgen INC. | $200.20 | 2023 | Tavneos, Vectibix, Nplate |
| Novartis Pharmaceuticals Corporation | $75.24 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $53.76 | 2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $48.58 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $41.68 | 2024-2025 | Enhertu |
| Abbvie INC. | $39.40 | 2025 | |
| Sobi, INC | $37.99 | 2024-2025 | |
| Inspire Medical Systems, INC. | $34.63 | 2025 | Inspire |
| Coherus Oncology, INC. | $31.68 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $23.57 | 2024 | Keytruda |
| Gilead Sciences, INC. | $20.94 | 2025 | Trodelvy |
| Incyte Corporation | $20.81 | 2023 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $18.36 | 2025 | Fruzaqla |
| Eisai INC. | $17.81 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $15.77 | 2024 | Kimmtrak |
| Axonics, INC. | $15.30 | 2023 | Axonics |
| Celgene Corporation | $15.21 | 2024 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $14.87 | 2024 | Tagrisso |
| Tersera Therapeutics LLC | $13.68 | 2024 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Ramahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.